Evidence map›Paper›PMID 36636673›Full record

ArticleCase reports in oncology

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report.

Takuya Nakagawa, Yoshihide Kawasaki, Satoko Sato, Hiromichi Katayama, Yohei Satake, Shuichi Shimada, Takuma Sato, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Takuya NakagawaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshihide KawasakiDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoko SatoDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Hiromichi KatayamaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yohei SatakeDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shuichi ShimadaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takuma SatoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoki KawamoritaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shinichi YamashitaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Koji MitsuzukaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Atsushi KohyamaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masaharu IshidaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hideo OhtsukaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Michiaki UnnoDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akihiro ItoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a rare case, free from systemic therapy, deferred cytoreductive nephrectomy was implemented in treating an advanced renal cell carcinoma with liver, lung, and splenic colon metastases. A 59-year-old man diagnosed with advanced renal cell carcinoma underwent deferred cytoreductive nephrectomy due to a partial response to systemic treatment after a period of 1 year. After the surgery, no additional treatment was implemented. Furthermore, after 10 months, the patient had no recurrence of renal cell carcinoma. Through a review of this case and deferred cases in the current literature, we could emphasize the importance of image evaluation and pathological findings as an indication for surgery and subsequent treatment options. However, there is room for debate with regards to the indications for deferred cytoreductive nephrectomy as well as a therapeutic strategy after the surgery. This report discusses the significance of deferred cytoreductive nephrectomy in terms of prognosis and quality-of-life improvement in advanced renal cancer.

Indexed as

Attenuation,CabozantinibDeferred cytoreductive nephrectomyImmunotherapyRenal cell carcinomaSize, and Structure criteriaThe Morphology,

Identifiers

PMID36636673
PMCPMC9830278
OpenAlexW4308541755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.